Dechra Pharmaceuticals (LON:DPH) Share Price Passes Above Two Hundred Day Moving Average of $2,877.09

Dechra Pharmaceuticals PLC (LON:DPHGet Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 2,877.09 ($36.30) and traded as high as GBX 3,704 ($46.74). Dechra Pharmaceuticals shares last traded at GBX 3,666 ($46.26), with a volume of 514,195 shares traded.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Berenberg Bank restated a “hold” rating and issued a GBX 2,850 ($35.96) price target on shares of Dechra Pharmaceuticals in a research report on Monday, February 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 3,112 ($39.27) price objective on shares of Dechra Pharmaceuticals in a research note on Tuesday, February 28th. Finally, JPMorgan Chase & Co. dropped their price objective on Dechra Pharmaceuticals from GBX 4,600 ($58.04) to GBX 4,000 ($50.47) and set an “overweight” rating for the company in a research note on Tuesday, March 7th.

Dechra Pharmaceuticals Price Performance

The company has a current ratio of 2.73, a quick ratio of 1.66 and a debt-to-equity ratio of 60.73. The stock has a market cap of £4.24 billion, a price-to-earnings ratio of 10,474.29, a PEG ratio of 1.42 and a beta of 0.71. The stock has a 50-day moving average price of GBX 3,031.22 and a two-hundred day moving average price of GBX 2,877.09.

Dechra Pharmaceuticals Cuts Dividend

The company also recently declared a dividend, which was paid on Thursday, April 13th. Shareholders of record on Thursday, March 9th were given a dividend of GBX 12.50 ($0.16) per share. The ex-dividend date of this dividend was Thursday, March 9th. This represents a yield of 0.4%. Dechra Pharmaceuticals’s dividend payout ratio is currently 12,857.14%.

Dechra Pharmaceuticals Company Profile

(Get Rating)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.

Recommended Stories

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with's FREE daily email newsletter.